Despite the persisting steatosis (Figure 7B), tempol administration completely prevented the induction of key pro-inflammatory (Tnfα and Il-1β) and fibrogenic (Tgfβ and αSMA) markers (Figure 7C,D), suggesting a liver protecting effect. This evidence concerns the gene ACTA1 and steatosis.